Publication:
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir

Simple item page
dc.contributor.authorManosuthi W.
dc.contributor.authorSungkanuparph S.
dc.contributor.authorRuxrungtham K.
dc.contributor.authorPrasithsirikul W.
dc.contributor.authorAthichathanabadi C.
dc.contributor.authorTantisiriwat W.
dc.contributor.authorBowonwatanuwong C.
dc.contributor.authorChumpathat N.
dc.contributor.authorChaovavanich A.
dc.date.accessioned2021-04-05T04:32:04Z
dc.date.available2021-04-05T04:32:04Z
dc.date.issued2008
dc.date.issuedBE2551
dc.description.abstract[No abstract available]
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of Acquired Immune Deficiency Syndromes. Vol 47, No.1 (2008), p.127-129
dc.identifier.doi10.1097/QAI.0b013e318157b0da
dc.identifier.issn15254135
dc.identifier.other2-s2.0-39049117418
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4190
dc.rights.holderScopus
dc.subject.otherAtazanavir
dc.subject.otherProteinase inhibitor
dc.subject.otherRitonavir
dc.subject.otherRNA directed DNA polymerase inhibitor
dc.subject.otherSaquinavir
dc.subject.otherVirus RNA
dc.subject.otherAtazanavir
dc.subject.otherOligopeptide
dc.subject.otherProteinase inhibitor
dc.subject.otherPyridine derivative
dc.subject.otherRitonavir
dc.subject.otherSaquinavir
dc.subject.otherAdult
dc.subject.otherAminotransferase blood level
dc.subject.otherBlood sampling
dc.subject.otherCD4 lymphocyte count
dc.subject.otherClinical article
dc.subject.otherControlled study
dc.subject.otherDNA polymorphism
dc.subject.otherDrug blood level
dc.subject.otherDrug efficacy
dc.subject.otherDrug safety
dc.subject.otherDrug tolerability
dc.subject.otherDyslipidemia
dc.subject.otherFemale
dc.subject.otherHigh performance liquid chromatography
dc.subject.otherHuman
dc.subject.otherHuman immunodeficiency virus infection
dc.subject.otherHyperbilirubinemia
dc.subject.otherLetter
dc.subject.otherLow drug dose
dc.subject.otherMale
dc.subject.otherPractice guideline
dc.subject.otherPriority journal
dc.subject.otherSalvage therapy
dc.subject.otherSide effect
dc.subject.otherSteady state
dc.subject.otherTreatment duration
dc.subject.otherTreatment outcome
dc.subject.otherVirus resistance
dc.subject.otherArticle
dc.subject.otherDrug administration
dc.subject.otherDrug combination
dc.subject.otherDrug Administration Schedule
dc.subject.otherDrug Therapy, Combination
dc.subject.otherHIV Infections
dc.subject.otherHIV Protease Inhibitors
dc.subject.otherHumans
dc.subject.otherOligopeptides
dc.subject.otherPyridines
dc.subject.otherRitonavir
dc.subject.otherSaquinavir
dc.titlePlasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir
dc.typeLetter
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-39049117418&doi=10.1097%2fQAI.0b013e318157b0da&partnerID=40&md5=9c6cb1be2c5626aefcfeb310a21297cf

Files

Collections

Scopus: Year 1983-2021